Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Launched by SHANGHAI CHANGZHENG HOSPITAL ·
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called IBI311 for people with inactive thyroid-associated ophthalmopathy (TAO), a condition linked to thyroid disease that affects the eyes. TAO can cause symptoms like eye swelling, discomfort, and in severe cases, vision problems or even blindness. IBI311 is a type of medicine designed to block certain signals in the body that cause eye tissue to grow and swell. Researchers want to see if IBI311 is both effective and safe for people with moderate to severe TAO that is currently inactive, meaning the disease isn’t actively worsening.
The study is open to adults with inactive moderate to severe TAO. Participants will receive IBI311 treatment and be closely monitored to see how well the medicine works and if there are any side effects. This trial aims to fill gaps in current knowledge about using IBI311 in this group of patients. If you or a loved one has inactive TAO and are interested in new treatment options, this study might be an opportunity to consider.
Gender
ALL
Eligibility criteria
About Shanghai Changzheng Hospital
Shanghai Changzheng Hospital, affiliated with the Second Military Medical University, is a leading medical institution in China known for its comprehensive clinical services and advanced research capabilities. With a commitment to improving patient outcomes and advancing medical knowledge, the hospital actively engages in clinical trials across various therapeutic areas. Its multidisciplinary team of healthcare professionals collaborates with researchers and industry partners to facilitate innovative studies, ensuring adherence to the highest ethical and regulatory standards. By leveraging its state-of-the-art facilities and expertise, Shanghai Changzheng Hospital aims to contribute significantly to the development of new treatments and therapies that enhance patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported